122 related articles for article (PubMed ID: 24589274)
1. Emerging therapy in hemoglobinopathies: lessons from the past and optimism for the future.
Vichinsky EP
Hematol Oncol Clin North Am; 2014 Apr; 28(2):xiii-xviii. PubMed ID: 24589274
[No Abstract] [Full Text] [Related]
2. [Present and future of ribonucleic acid interference].
Pinazo-Durán MD; Zanón-Moreno V; Vinuesa Silva I; García Medina JJ; Benítez del Castillo J
Arch Soc Esp Oftalmol; 2015 Jan; 90(1):1-3. PubMed ID: 25660458
[No Abstract] [Full Text] [Related]
3. The changing face of vascular interventional radiology: the future role of pharmacotherapies and molecular imaging.
Tapping CR; Bratby MJ
Cardiovasc Intervent Radiol; 2013 Aug; 36(4):904-12. PubMed ID: 23636247
[TBL] [Abstract][Full Text] [Related]
4. Lenti in red: progress in gene therapy for human hemoglobinopathies.
von Kalle C; Baum C; Williams DA
J Clin Invest; 2004 Oct; 114(7):889-91. PubMed ID: 15467825
[TBL] [Abstract][Full Text] [Related]
5. Hopes, Promises, and Future Directions of Gene and Cell Therapies in France.
Cartier N; Cordelier P
Hum Gene Ther; 2016 Feb; 27(2):96-7. PubMed ID: 26886830
[No Abstract] [Full Text] [Related]
6. Gene Therapy for Hemoglobinopathies: Tremendous Successes and Remaining Caveats.
Malik P
Mol Ther; 2016 Apr; 24(4):668-70. PubMed ID: 27081721
[No Abstract] [Full Text] [Related]
7. Mesoporous silica nanoparticles: a potential targeted delivery vector for reproductive biology?
Barkalina N; Jones C; Coward K
Nanomedicine (Lond); 2014 Apr; 9(5):557-60. PubMed ID: 24827836
[No Abstract] [Full Text] [Related]
8. Gene therapy for the hemoglobin disorders: past, present, and future.
Persons DA; Nienhuis AW
Proc Natl Acad Sci U S A; 2000 May; 97(10):5022-4. PubMed ID: 10805762
[No Abstract] [Full Text] [Related]
9. [Beating cancer with synthetic genes: towards more effective treatments through autonomous genetic programs].
Morel M
Med Sci (Paris); 2017; 33(6-7):591-593. PubMed ID: 28990556
[No Abstract] [Full Text] [Related]
10. Prospects of gene therapy for hemoglobinopathies.
Steinberg MH
Am J Med Sci; 1991 Nov; 302(5):298-303. PubMed ID: 1750450
[TBL] [Abstract][Full Text] [Related]
11. Non-viral gene therapy.
Treco DA; Selden RF
Mol Med Today; 1995 Oct; 1(7):314-21. PubMed ID: 9415171
[TBL] [Abstract][Full Text] [Related]
12. Precision Medicine.
Health Aff (Millwood); 2018 May; 37(5):688-689. PubMed ID: 29733721
[TBL] [Abstract][Full Text] [Related]
13. Genetic treatment of the haemoglobinopathies: recombinations and new combinations.
Sadelain M
Br J Haematol; 1997 Aug; 98(2):247-53. PubMed ID: 9266916
[No Abstract] [Full Text] [Related]
14. Novel approaches toward managing the micromanagers: 'non-toxic' but effective.
Diekwisch TG
Gene Ther; 2016 Oct; 23(10):697-698. PubMed ID: 27383252
[No Abstract] [Full Text] [Related]
15. Targeted nanotherapeutics in cancer.
Shiekh FA
Int J Nanomedicine; 2014; 9():1627-8. PubMed ID: 24741302
[No Abstract] [Full Text] [Related]
16. Genetic tumor profiling and genetically targeted cancer therapy.
Goetsch CM
Semin Oncol Nurs; 2011 Feb; 27(1):34-44. PubMed ID: 21255711
[TBL] [Abstract][Full Text] [Related]
17. The 11th conference on hemoglobin switching. Orcas Island, Washington, USA. October 2-6, 1998. Abstracts.
Blood Cells Mol Dis; 1998 Dec; 24(4):462-521. PubMed ID: 9880242
[No Abstract] [Full Text] [Related]
18. [Hemoglobinopathies: molecular, genetic and clinical aspects].
de Araújo JT; Ribeiro VS; de Araújo RA
Rev Hosp Clin Fac Med Sao Paulo; 1987; 42(6):260-6. PubMed ID: 3455557
[No Abstract] [Full Text] [Related]
19. [Therapy of hemoglobin diseases].
Kleihauer E
Monatsschr Kinderheilkd (1902); 1980 Jan; 128(1):9-10. PubMed ID: 7360128
[No Abstract] [Full Text] [Related]
20. Targeted cancer therapies: current status and future directions.
Starakis I
Curr Med Chem; 2011; 18(11):1573-4. PubMed ID: 21428889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
